In the wake of the increase in Current Liabilities in the first quarter 2022, Quick Ratio fell to 0.94 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Meridian Bioscience Inc in first quarter 2022. While Quick Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 2345 to 3238.

Explain Quick Ratio?
How much Cash & cash equivalents VIVO�s has?
What are VIVO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VIVO Quick Ratio	(Dec 31 2022) Q1	(Sep 30 2022) Q4	(Jun 30 2022) Q3	(Mar 31 2022) Q2	(Dec 31 2021) Q1
Y / Y Current Liabilities Change	57.32 %	22.89 %	64.42 %	12.23 %	-7.22 %
Y / Y Cash & cash equivalent Change	1.88 %	63.66 %	19.25 %	20.69 %	15.09 %
Quick Ratio MRQ	0.94	1.41	1.38	1.35	1.46
VIVO's Total Ranking	# 3238	# 2345	# 2370	# 1857	# 2297
Seq. Current Liabilities Change	35.59 %	-3.97 %	6.88 %	13.05 %	5.91 %
Seq. Cash & cash equivalent Change	-9.03 %	-2.44 %	9.15 %	5.17 %	46.13 %

Quick Ratio first quarter 2022 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 17
Healthcare Sector	# 1019
Overall Market	# 3238

Quick Ratio Statistics
High	Average	Low
6.76	2.41	0.94
(Jun 30 2010)		(Dec 31 2022)

Financial Statements
Meridian Bioscience Inc 's Current Liabilities	$ 79 Millions	Visit VIVO's Balance sheet
Meridian Bioscience Inc 's Cash & cash equivalent	$ 74 Millions	Visit VIVO's Balance sheet
Source of VIVO's Sales		Visit VIVO's Sales by Geography

Cumulative Meridian Bioscience Inc 's Quick Ratio

VIVO's Quick Ratio for the trailling 12 Months

VIVO Quick Ratio	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months	(Mar 31 2022) 12 Months	(Dec 31 2021) 12 Months
Y / Y Current Liabilities TTM Growth	37.6 %	19.53 %	12.34 %	-3.52 %	-0.36 %
Y / Y Cash & cash equivalent TTM Growth	23.31 %	27.52 %	12.95 %	10.46 %	11.4 %
Quick Ratio TTM	1.25	1.4	1.32	1.41	1.39
Total Ranking TTM	# 5829	# 5805	# 4518	# 599	# 1931
Seq. Current Liabilities TTM Growth	12.74 %	5.05 %	12.43 %	3.34 %	-2.07 %
Seq. Cash & cash equivalent TTM Growth	0.44 %	11.22 %	5.01 %	5.12 %	3.87 %

Quick ratio ranking by company, industry and sector >> Back to VIVO Financial Strength Comparisons >> Go to Compare VIVO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2022 to $78.58 millions, cumulative Quick Ratio decreased to 1.25 below the Meridian Bioscience Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 22 other companies have achieved higher Quick Ratio than Meridian Bioscience Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 5805 to 5829.

Explain Quick Ratio?
How much Cash & cash equivalents VIVO�s has?
What are VIVO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 23
Healthcare Sector	# 1229
Within the Market	# 5829

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.23	2.22	1.22
(Dec 31 2015)		(Mar 31 2021)

Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Dec 31 2022 MRQ Cash & cash equivalent	Dec 31 2022 MRQ Current Liabilities
Qc Technologies Inc	1.79	$ 4.836 Millions	$ 2.703 Millions
Lantheus Holdings Inc	1.67	$ 415.652 Millions	$ 249.181 Millions
Insight Molecular Diagnostics Inc	1.65	$ 19.993 Millions	$ 12.106 Millions
Achieve Life Sciences Inc	1.11	$ 24.771 Millions	$ 22.360 Millions
Meridian Bioscience Inc	0.94	$ 74.098 Millions	$ 78.577 Millions
Aspira Women s Health inc	0.82	$ 13.306 Millions	$ 16.174 Millions
Myriad Genetics Inc	0.63	$ 114.900 Millions	$ 181.100 Millions
Volitionrx Limited	0.63	$ 10.867 Millions	$ 17.386 Millions
Immucell Corporation	0.53	$ 5.792 Millions	$ 10.930 Millions
Quotient Limited	0.40	$ 11.934 Millions	$ 29.631 Millions
Trinity Biotech Plc	0.35	$ 8.412 Millions	$ 23.754 Millions
Nymox Pharmaceutical Corporation	0.35	$ 1.431 Millions	$ 4.041 Millions
Quidelortho Corp	0.35	$ 345.000 Millions	$ 995.400 Millions
Navidea Biopharmaceuticals Inc	0.20	$ 1.996 Millions	$ 9.923 Millions

Date modified: 2026-09-08T15:10:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.